Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125)

S Loi; S Dushyanthen; PA Beavis; R Salgado; C Denkert; P Savas; S Combs; DL Rimm; JM Giltnane; MV Estrada; V Sanchez; ME Sanders; RS Cook; MA Pilkinton; SA Mallal; K Wang; VA Miller; PJ Stephens; R Yelensky; FD Doimi; H Gomez; SV Ryzhov; PK Darcy; CL Arteaga; JM Balko

Journal article

Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125)

S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, S Combs, DL Rimm, JM Giltnane, MV Estrada, V Sanchez, ME Sanders, RS Cook, MA Pilkinton, SA Mallal, K Wang, VA Miller, PJ Stephens, R Yelensky, FD Doimi Show all

Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2019

DOI: 10.1158/1078-0432.CCR-18-4264

Abstract

In the original version of this article (1), the stated disclosure of the author Carlos L. Arteaga is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125)

Abstract

University of Melbourne Researchers

Citation metrics

Keywords